Mallinckrodt to acquire Sucampo Pharmaceuticals for $1.2B. The cash tender offer equates to $18 per share.
Mallinckrodt to take ownership of Amitiza, a leading medicine servicing the branded constipation market (as well as other molecules for the orphan diseases niche).
This is an abbreviated version of the in-depth Integrated BioSci Report available in advance to our marketplace subscribers.
READ FULL ARTICLE HERE